BR112014014427A2 - estratégia geral para seleção de biblioteca de anticorpos - Google Patents

estratégia geral para seleção de biblioteca de anticorpos

Info

Publication number
BR112014014427A2
BR112014014427A2 BR112014014427A BR112014014427A BR112014014427A2 BR 112014014427 A2 BR112014014427 A2 BR 112014014427A2 BR 112014014427 A BR112014014427 A BR 112014014427A BR 112014014427 A BR112014014427 A BR 112014014427A BR 112014014427 A2 BR112014014427 A2 BR 112014014427A2
Authority
BR
Brazil
Prior art keywords
library selection
antibody library
overall strategy
selective
catalase
Prior art date
Application number
BR112014014427A
Other languages
English (en)
Inventor
Maass Alexander
Kolmar Harald
Becker Stefan
Heiseler Tim
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112014014427A2 publication Critical patent/BR112014014427A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/08—Methods of screening libraries by measuring catalytic activity

Abstract

resumo patente de invenção: "estratégia geral para seleção de biblioteca de anticorpos". a presente invenção refere-se a um método aplicável geralmente para a ligação covalente seletiva de uma molécula repórter a uma entidade replicante que permite obter ligantes específicos a partir de um único ciclo de seleção de biblioteca. por exemplo, biotinilação seletiva de partículas de fagos e células de leveduras exibindo um ligante para qualquer dado alvo pode ser obtida via aplicação de uma reação de enzima acoplada que inclui uma peroxidase, uma oxidase e uma catalase.
BR112014014427A 2011-12-16 2012-12-14 estratégia geral para seleção de biblioteca de anticorpos BR112014014427A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11009901.7A EP2605014A1 (en) 2011-12-16 2011-12-16 General strategy for antibody library screening
PCT/EP2012/005162 WO2013087215A1 (en) 2011-12-16 2012-12-14 General strategy for antibody library screening

Publications (1)

Publication Number Publication Date
BR112014014427A2 true BR112014014427A2 (pt) 2017-06-13

Family

ID=47428549

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014427A BR112014014427A2 (pt) 2011-12-16 2012-12-14 estratégia geral para seleção de biblioteca de anticorpos

Country Status (14)

Country Link
US (1) US9733240B2 (pt)
EP (2) EP2605014A1 (pt)
JP (1) JP2015505675A (pt)
KR (1) KR20140104493A (pt)
CN (1) CN103998934A (pt)
AU (1) AU2012351104B2 (pt)
BR (1) BR112014014427A2 (pt)
CA (1) CA2859247A1 (pt)
EA (1) EA201400713A1 (pt)
ES (1) ES2742303T3 (pt)
IL (1) IL233133A (pt)
MX (1) MX2014007094A (pt)
SG (1) SG11201403073PA (pt)
WO (1) WO2013087215A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113999772A (zh) * 2021-09-29 2022-02-01 佛山奥素博新科技有限公司 一种基于数字微流控系统的酵母表面展示方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
EP1634074B1 (en) * 2003-06-12 2009-08-12 Perkinelmer Las, Inc. Hydrolytic substrates for an analyte-dependent enzyme activation system
JP2008228637A (ja) * 2007-03-20 2008-10-02 Tokushima Bunri Univ 蛍光相関分光測定法を用いた過酸化水素量の測定方法及びその利用方法
KR101553723B1 (ko) * 2007-07-13 2015-09-16 네스텍 소시에테아노님 항체­기반 어레이를 사용한 폐 암 치료를 위한 약물 선별법
US8685370B2 (en) * 2008-03-14 2014-04-01 Visen Medical, Inc. Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
CA2761777A1 (en) * 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy

Also Published As

Publication number Publication date
IL233133A (en) 2017-12-31
AU2012351104A1 (en) 2014-07-31
US20140357514A1 (en) 2014-12-04
WO2013087215A1 (en) 2013-06-20
CN103998934A (zh) 2014-08-20
EP2791677A1 (en) 2014-10-22
EP2791677B1 (en) 2019-05-15
MX2014007094A (es) 2014-07-22
KR20140104493A (ko) 2014-08-28
EA201400713A1 (ru) 2014-12-30
JP2015505675A (ja) 2015-02-26
EP2605014A1 (en) 2013-06-19
CA2859247A1 (en) 2013-06-20
IL233133A0 (en) 2014-07-31
AU2012351104B2 (en) 2018-08-09
SG11201403073PA (en) 2014-07-30
US9733240B2 (en) 2017-08-15
ES2742303T3 (es) 2020-02-13

Similar Documents

Publication Publication Date Title
AU2018200640B2 (en) Humanization of rabbit antibodies using a universal antibody framework
AR060583A1 (es) Anticuerpo de c- kit humanizado
BR112015004980A2 (pt) loci de desempenho de fad2 e proteínas-alvo de ligação sítio-específicas correspondentes que têm a capacidade de induzir rompimentos direcionados
MX344040B (es) Anticuerpos mejorados de la clase inmonoglubina g4 (igg4).
SG170021A1 (en) Compositions and methods useful for culturing differentiable cells
WO2012106385A3 (en) Methods of identifying multiple epitopes in cells
CR20110283A (es) Combinaciones antitumores que contienen anticuerpos que reconocen especificamente cd 38 y ciclofosfamida
EA201391245A1 (ru) Интеррогативные клеточные анализы и их применение
BR112013026828A2 (pt) polipeptídeos de anticorpo que antagonizam cd40
BR112013033661A2 (pt) inibidores de ativação de células t
WO2010048417A3 (en) Perfusion bioreactors, cell culture systems, and methods for production of cells and cell-derived products
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
BR112014025384A8 (pt) método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
MA34488B1 (fr) Composition pesticides
WO2012129242A3 (en) Isolation of polymerase-nucleic acid complexes and loading onto substrates
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
CL2013001089A1 (es) Anticuerpos que se une especificamente a tnfalfa humano; composicion farmacéutica que la comprende; molécula de ácido nucleico aislado; vector; metodo para reducir la tendencia a la agregación de un anticuerpo.
CL2012000788A1 (es) Anticuerpo aislado que se une a fibrina o fibronogeno; metodo para aliviar un sintoma de una patologia asociada con la union de mac-1 a fibrina o fibrinogeno; composicion farmaceutica; kit; vector; celula; metodo para generar anticuerpo; metodo para analizar un ligando que se une a un receptor mac-1.
WO2010138814A3 (en) Disrupting fcrn-albumin interactions
ATE512386T1 (de) Umskalierung des sollastigmatismus für andere additionen
BR112015013697A2 (pt) método para ativar célula t auxiliar
BR112014004543A2 (pt) método de síntese de proteínas
WO2009124294A3 (en) Pharmaceutical compositions for binding sphingosine-1-phosphate
BR112015022529A2 (pt) meios de cultura de células e processos de produção de anticorpo

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]